Cambridge Team First to Grow Smooth Muscle Cells from Patient Skin Cells
News Jan 26, 2012
The team has for the first time discovered a method of generating different types of vascular smooth muscle cells (SMCs) - the cells which make up the walls of blood vessels - using cells from patients' skin.
Cardiovascular disease is the leading cause of death in the world**. These deaths are mainly caused by the hardening and subsequent blockage of blood vessels due to the accumulation of fatty materials, a condition called atherosclerosis. As not all patients are suitable for conventional stenting or bypass treatment, an option in the future may be to grow new blood vessels to bypass their own blocked vessels.
The team from Cambridge worked with embryonic stem cells and reprogrammed skin cells, collectively known as human pluripotent stem cells (hPSCs), which have the potential to form any cell type in the body. They discovered a method of creating all the major vascular smooth muscle cells in high purity using hPSCs which can also be easily scaled up for production of clinical-grade SMCs. This is the first time that such a system has been developed and will open the door for comparative studies on different subtypes of SMCs to be carried out, which are otherwise extremely difficult to obtain from patients.
The scientists created three subtypes of SMCs from different embryonic tissues which they reproduced in the culture dish and showed that the various SMC subtypes responded differently when exposed to substances that cause vascular diseases. They concluded that differences in the embryonic origin play a role in their susceptibility to diseases and may play a part in determining where and when common vascular diseases such as aortic aneurysms or atherosclerosis develop.
Dr Alan Colman, Principle Investigator of the Institute of Medical Biology under A*STAR and Executive Director of the Singapore Stem Cell Consortium, said, "This is a major advance in vascular disease modelling using patient-derived stem cells. The development of robust methods to make multiple, distinct smooth muscle subtypes provides tools for scientists to model and understand a greater range of vascular diseases in a culture dish than was previously available. It is a significant stride forward in being able to construct new blood vessels which will benefit a whole range of patients including those with cardiovascular diseases, renal failure and genetic disorders such as Marfans Syndrome that affect the normal function of their blood vessels."
Dr Lim Khiang Wee, Executive Director of the A*STAR Graduate Academy (A*GA), said, "Christine's work reflects the calibre of our scholars - they do excellent research and grow into scientists who will contribute to Singapore when they return."
Ms Christine Cheung is a National Science Scholarship (NSS) scholar and is doing her final year PhD studies at Cambridge University (UK). The NSS scholarship is one of the programmes offered by A*GA, to attract and develop outstanding young talent passionate about research who will spearhead Singapore's drive to becoming Asian's Innovation Capital.
* The paper "Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility" was published on Nature Biotechnology's website on 15 January. Ms Christine Cheung is funded by a National Science Scholarship from the A*STAR (Agency for Science, Technology and Research, Singapore). The other authors are Dr Andreia S Bernardo, Dr Matthew W B Trotter, Prof Roger A Pedersen & Dr Sanjay Sinha (Christine's PhD supervisor). Additional funding was provided by the Wellcome Trust and the Medical Research Council.
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE